ESR1 and breast carcinoma: We also observed that LLGL2low/SLC7A5low showed longer survival compared with LLGL2high/SLC7A5high and a positive trend of longer survival compared with other combination groups in Erα-positive breast cancer patients receiving adjuvant tamoxifen therapy.